Vaccination rates among adults with sickle cell disease: a single-center study from the Eastern Mediterranean region of Turkey Vaccination status of adult patients with sickle cell disease

Main Article Content

Mahmut Bakir Koyuncu
Cagatay Cavusoglu
Elif Sahin Horasan
Anil Tombak


Objective: Being vaccinated against encapsulated bacteria is the most efficient way to reduce painful crises and mortality in patients with sickle cell disease (SCD). Although guidelines strongly recommend vaccination, vaccination rates remain under the desired levels. In this study, we aim to determine vaccination rates and understand the reasons for non-vaccination in patients with SCD.

Material and methods: We included 76 patients with SCD in this study. We administered a questionnaire consisting of 21 questions and examined the electronic vaccination records of these patients.

Results: The vaccination rates were 36.5% for the pneumococcal vaccine, 22.4% for the Hemophilus influenza type b vaccine, and 19.7% for the meningococcal vaccine. Residence in rural areas and annual control visits were found to increase the pneumococcal vaccination rates (OR: 11.90, 95% CI: 2.549–56.107, p = 0.002 and OR: 9.08, 95% CI: 1.120–73.624, p = 0.039, respectively) and meningococcal vaccination rates (OR: 2.75, 95% CI: 1.464–5.186, p = 0.002 and OR:1.36, 95% CI: 1.159–1.610, p < 0.001, respectively). Thirty-four (44.7%) of the cases stated that their doctors did not give any information about these vaccinations.

Conclusion: Vaccination rates are low in patients with SCD. Residence in rural areas, annual control visits, educational level, and doctor recommendations affect these vaccination rates.


Download data is not yet available.

Article Details

How to Cite
Koyuncu, M. B., Cavusoglu, C., Sahin Horasan, E. ., & Tombak, A. (2021). Vaccination rates among adults with sickle cell disease: a single-center study from the Eastern Mediterranean region of Turkey: Vaccination status of adult patients with sickle cell disease. Medical Science and Discovery, 8(11), 645–649.
Research Article
Received 2021-11-11
Accepted 2021-11-22
Published 2021-11-23


Tamouza R, Neonato MG, Busson M, Marzais F, Girot R, Labie D, et al. Infectious complications in sickle cell disease are influenced by HLA class II alleles. Hum Immunol. 2002;63(3):194-9.

Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. Int J Infect Dis. 2010;14(1):e2-e12.

Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004;103(11):4023-7.

John AB, Ramlal A, Jackson H, Maude GH, Sharma AW, Serjeant GR. Prevention of pneumococcal infection in children with homozygous sickle cell disease. Br Med J (Clin Res Ed). 1984;288(6430):1567-70.

Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama. 2014;312(10):1033-48.

Walsh KE, Cutrona SL, Kavanagh PL, Crosby LE, Malone C, Lobner K, et al. Medication adherence among pediatric patients with sickle cell disease: a systematic review. Pediatrics. 2014;134(6):1175-83.

Beverung LM, Brousseau D, Hoffmann RG, Yan K, Panepinto JA. Ambulatory quality indicators to prevent infection in sickle cell disease. Am J Hematol. 2014;89(3):256-60.

Nero AC, Akuete K, Leasure Reeves S, Dombkowski KJ. Pneumococcal vaccination rates in children with sickle cell disease. J Public Health Manag Pract. 2014;20(6):587-90.

Wagner AL, Shrivastwa N, Potter RC, Lyon-Callo SK, Boulton ML. Pneumococcal and Meningococcal Vaccination among Michigan Children with Sickle Cell Disease. J Pediatr. 2018;196:223-9.

Korur A, Asma S, Gereklioglu C, Solmaz S, Boga C, Ozsahin AK, et al. Significance of electronic health records: A comparative study of vaccination rates in patients with sickle cell disease. Pak J Med Sci. 2017;33(3):549-53.

Fujino T, Goyama S, Sugiura Y, Inoue D, Asada S, Yamasaki S, et al. Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. Nature Communications. 2021;12(1):1826.

Halasa NB, Shankar SM, Talbot TR, Arbogast PG, Mitchel EF, Wang WC, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428-33.

Infanti LM, Elder JJ, Franco K, Simms S, Statler VA, Raj A. Immunization Adherence in Children With Sickle Cell Disease: A Single-Institution Experience. J Pediatr Pharmacol Ther. 2020;25(1):39-46.

Howard-Jones M, Randall L, Bailey-Squire B, Clayton J, Jackson N. An audit of immunisation status of sickle cell patients in Coventry, UK. J Clin Pathol. 2009;62(1):42-5.

Sobota AE, Kavanagh PL, Adams WG, McClure E, Farrell D, Sprinz PG. Improvement in influenza vaccination rates in a pediatric sickle cell disease clinic. Pediatric Blood & Cancer. 2015;62(4):654-7.

Daley MF, Barrow J, Pearson K, Crane LA, Gao D, Stevenson JM, et al. Identification and recall of children with chronic medical conditions for influenza vaccination. Pediatrics. 2004;113(1 Pt 1):e26-33.

Bundy DG, Muschelli J, Clemens GD, Strouse JJ, Thompson RE, Casella JF, et al. Preventive Care Delivery to Young Children With Sickle Cell Disease. Journal of pediatric hematology/oncology. 2016;38(4):294-300.

Most read articles by the same author(s)